Results 11 to 20 of about 1,425 (166)

Consenso mexicano para el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática

Revista de Gastroenterología de México, 2018
Resumen: Estas guías constituyen una actualización de las guías publicadas en 2007. Desde ese año, los conocimientos acerca de la fisiopatología, así como las opciones terapéuticas, han evolucionado rápidamente, con la aprobación de nuevos agentes, la ...
J.K. Yamamoto-Furusho, Y. Gutiérrez-Grobe, J.G. López-Gómez, F. Bosques-Padilla, J.L. Rocha-Ramírez   +4 more
doaj   +1 more source

The Mexican consensus on the diagnosis and treatment of ulcerative colitis

Revista de Gastroenterología de México (English Edition), 2018
The guidelines presented herein are an updated version of the recommendations published in 2007. Since then, there has been a rapid advance in the knowledge about the pathophysiology of ulcerative colitis and its therapeutic options.
J.K. Yamamoto-Furusho, Y. Gutiérrez-Grobe, J.G. López-Gómez, F. Bosques-Padilla, J.L. Rocha-Ramírez   +4 more
doaj   +1 more source

Epidemiología de la enfermedad inflamatoria intestinal

Revista Médica Clínica Las Condes, 2019
Resumen: La Enfermedad Inflamatoria Intestinal (EII) engloba principalmente a la Colitis ulcerosa (CU) y a la Enfermedad de Crohn (EC). Ambas patologías son de carácter crónico y de etiología desconocida.
Carolina Figueroa
doaj   +1 more source

Manifestaciones clínicas y endoscópicas en enfermedad inflamatoria intestinal

Revista Médica Clínica Las Condes, 2019
Resumen: La Colitis Ulcerosa y la Enfermedad de Crohn, son enfermedades crónicas, inmunomediadas, que afectan al tubo digestivo, alternando períodos de inactividad con períodos de crisis durante los cuales el paciente presenta manifestaciones clínicas ...
Macarena Gompertz, Rocío Sedano
doaj   +1 more source

Adaptation of the International Consortium for Health Outcomes Measurement Standard Set for Inflammatory Bowel Disease for Routine Collection in Clinical Practice

JCC Plus, Volume 1, Issue 4, July 2026.
ABSTRACT Background and Aims Value‐based healthcare (VBHC) is based on evaluating clinical interventions according to their ability to improve outcomes and costs to finally enhance quality of care. As part of an initiative to introduce VBHC in inflammatory bowel disease (IBD), our project aimed to adapt the International Consortium for Health Outcomes ...
Xavier Calvet, Iago Rodríguez‐Lago, Jose‐Lázaro Pérez‐Calle, Hugo Bronchalo‐Bautista, Elena Barbazán‐García, on behalf of the EEImprove Collaborative Project TEam, Alberto Vegas‐Miguel, Alicia Diaz‐Redondo, Ane Fullaondo‐Zabala, Carles Illa, Celia Albaladejo Blanco, Daniel Ceballos, Ignacio Marín‐Jiménez, Jesus Barrio Andres, Jesús Gonzalo Gómez Gómez, Jone Ortiz de Zaarate Sagastagoitia, Juan Manuel Sánchez Lledó, Laura Gómez‐Irwin, Luis Alberto Menchen Viso, Maite Zabala Ugarteburu, María Carme Nicolás Herrerías, María Dolores Martín‐Arranza, María Esteve Comas, María Mercedes Ortiz Otero, Mirari San Felix Carrasco, Mónica Sierra‐Ausin, Monsterrat Aceituno Quintanilla, Olga Merino Ochoa, Pilar López Serrano, Raúl Martín Puentes, San José Fernando Bermejo, Susana Castelo Zas, Susana Lorenzo Martínez, Yamile Zabana   +33 more
wiley   +1 more source

Assessment of the influence of the inflammatory process on the activation of blood platelets and morphological parameters in patients with ulcerative colitis (<i>colitis ulcerosa</i>)

Folia Histochemica et Cytobiologica, 2011
Ulcerative colitis (<i>colitis ulcerosa</i>) is a non-specific inflammatory bowel disease of unknown etiology. The symptoms which are observed in the course of ulcerative colitis are: an increase in the number of leukocytes and blood ...
Halina Kemona, Joanna Matowicka-Karna, Beata Polińska   +2 more
doaj   +1 more source

Use Patterns of Novel Janus Kinase Inhibitors After the First Safety Alerts: A Nationwide Register‐Based Time Series Analysis

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Purpose Janus kinase inhibitors (JAKi) are medicines used to treat inflammatory rheumatic musculoskeletal diseases (IRMDs) and inflammatory bowel diseases (IBDs). In Europe, JAKis received marketing authorisation in 2017 for rheumatoid arthritis.
Jarno Rutanen, Pekka Heino, Kati Sarnola, Terhi Kurko   +3 more
wiley   +1 more source

Weighing the Benefits of Improving the Iron Status Against the Risk of Overload—A Narrative Review on Oral Iron Supplementation in Premenopausal Women

BioFactors, Volume 52, Issue 3, May/June 2026.
Iron deficiency is a global phenomenon, particularly prevalent among menstruating females due to dietary factors and uterine bleeding. As first‐line therapy, oral iron therapy effectively improves quality of life but requires consideration of adverse effects. ABSTRACT To this day, women of childbearing age remain the largest group at high risk for iron
Katharina Jans, Patricia Huebbe, Anna P. Kipp, Gerald Rimbach   +3 more
wiley   +1 more source

TRATAMIENTO QUIRÚRGICO DE LA COLITIS ULCEROSA

Revista Médica Clínica Las Condes, 2019
Resumen: El tratamiento médico de pacientes con colitis ulcerosa se basa en aminosalicilatos, corticoides, inmunomoduladores y en los últimos años en terapia biológica predominantemente con anti-TNF.
Udo Kronberg
doaj   +1 more source

Epidemiología, carga de la enfermedad y tendencias de tratamiento de la enfermedad inflamatoria intestinal en México

Revista de Gastroenterología de México, 2020
Resumen: Introducción y objetivos: En México no existe información sistematizada para determinar/monitorizar la carga de la enfermedad inflamatoria intestinal (EII).
J.K. Yamamoto-Furusho, F.J. Bosques-Padilla, L. Charúa-Guindic, T. Cortés-Espinosa, R.M. Miranda-Cordero, A. Saez, Y. Ledesma-Osorio   +6 more
doaj   +1 more source